Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for cancer therapy

a cancer therapy and cancer technology, applied in the field of cancer therapy, can solve the problems of multiple myeloma remaining incurable, bone marrow failure, hypercalcemia, renal failure, etc., and achieve the effect of preventing the progression of multiple myeloma

Inactive Publication Date: 2019-05-02
TAKEDA PHARMA CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes maintenance therapies that can prevent multiple myeloma from coming back or progressing in cancer patients who have undergone a primary cancer therapy.

Problems solved by technology

Multiple myeloma is characterized by the accumulation of plasma cells in the bone marrow (and other organs) and can result in bone marrow failure, bone destruction, hypercalcemia, and renal failure.
Despite more therapeutic options, multiple myeloma remains incurable, and patients with early stage cancer remain at risk for relapse after their initial therapy.
Patients become refractory to approved therapies and ultimately are left with no alternative treatment options.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for cancer therapy
  • Methods for cancer therapy
  • Methods for cancer therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0031]The present disclosure provides various methods for treating cancer, or preventing cancer recurrence or progression. In the first aspect, the disclosure provides administering to a cancer patient a compound of formula (I), or a pharmaceutically acceptable salt thereof. In another aspect, the disclosure provides a dosing schedule of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as a maintenance therapy to a patient who has undergone a primary cancer therapy and responded. In a further aspect, the disclosure provides maintenance therapy comprising a proteasome inhibitor of formula (IIIa), or a pharmaceutically acceptable salt thereof, to improve and maintain response for patients who have undergone a primary cancer therapy.

[0032]In another aspect, the disclosure provides maintenance therapy comprising a proteasome inhibitor of formula (IIIa), or a pharmaceutically acceptable salt thereof, to prevent patients from cancer recurrence or progression.

[0033...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
timeaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

The present disclosure relates to methods or dosing regimens comprising a proteasome inhibitor of formula (I), or a pharmaceutically acceptable salt thereof,for treating cancer, or preventing cancer recurrence or progression; wherein ring A, Z1 and Z2 are as defined herein.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to U.S. Provisional Application No. 62 / 000,991, filed May 20, 2014, U.S. Provisional Application No. 62 / 019,600, filed Jul. 1, 2014 and U.S. Provisional Application No. 62 / 088,154, filed Dec. 5, 2014. The entire contents of the aforementioned applications are incorporated herein by reference.FIELD OF THE INVENTION[0002]The present disclosure relates to methods or dosing regimens comprising proteasome inhibitors of formula (I) for treating cancer, or preventing cancer recurrence or progression.BACKGROUND OF THE INVENTION[0003]Cancer has a major impact on society in the United States and across the world. Cancer is the second most common cause of death in the US, exceeded only by heart disease, accounting for nearly 1 of every 4 deaths. The National Cancer Institute estimates that in 2015, approximately 1,658,370 new cases of cancer will be diagnosed in the United States and 589,430 people will die from the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/69A61K31/454A61K31/426A61K31/407A61K31/353A61K31/198A61K9/48A61K38/07A61K38/06A61K38/05A61K31/145
CPCA61K31/69A61K31/454A61K31/426A61K31/407A61K31/353A61K31/198A61K9/4866A61K38/07A61K38/06A61K38/05A61K9/485A61K9/4858A61K31/145A61K2300/00A61P35/00A61K45/06
Inventor HUI, AI-MINLABOTKA, RICHARDGUPTA, NEERAJVENKATAKRISHNAN, KARTHIKLIU, GUOHUI
Owner TAKEDA PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com